L-methionine suppresses pathological sequelae of cis-platinum in the rat.

Abstract

The pathological changes characteristically observed in the kidney, bone marrow, thymus, spleen, and duodenum of the rat given 12.2 mg/kg of cis-platinum (CDDP) ip are reduced or eliminated when a CDDP solution containing a 20-fold excess of L-methionine to cis-platinum is administered. L-Methionine was also effective in reducing the renal toxicity induced by CDDP when given orally 20 min before the iv administration of 7.5 mg CDDP/kg. L-Methionine did not compromise the efficacy of CDDP when the antitumor activity of the combination of L-methionine and CDDP was measured against the Walker 256 carcinosarcoma in the rat. No significant reduction in the antitumor activity of the CDDP resulted from the parenteral administration of L-Methionine when evaluated against the L1210 murine leukemia. The oral administration of L-methionine (500 mg/kg) 30 min after the administration of CDDP has no significant effect on the antitumor activity of CDDP in mice bearing the L1210 murine leukemia. The results suggest that L-methionine may have some practical utility in the control of certain aspects of CDDP toxicity.

• Authors: M A Basinger, M M Jones, M A Holscher
• Journal: Fundamental and applied toxicology : official journal of the Society of Toxicology (Fundam Appl Toxicol) Vol. 14 Issue 3 Pg. 568-77 (Apr 1990) ISSN: 0272-0590 [Print] United States
• PMID: 2340984 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Platinum
• Methionine
• Creatinine
• Cisplatin

Topics

• Animals
• Blood Urea Nitrogen
• Bone Marrow (pathology)
• Carcinoma 256, Walker (drug therapy)
• Cisplatin (antagonists & inhibitors, therapeutic use, toxicity)
• Creatinine (blood)
• Female
• Kidney (pathology)
• Leukemia L1210 (drug therapy)
• Methionine (pharmacology)
• Platinum (pharmacokinetics)
• Rats
• Rats, Inbred Strains
• Spleen (pathology)
• Thymus Gland (pathology)